Clinical trial · Interventional
Evaluation of the Mixture Myoinositol:D-chiro-inositol 3.6:1 in Women With Polycystic Ovary Syndrome
Comparison of the Effect of a Combination of Myoinositol:D-chiro-inositol With Low Proportion of DCI (40:1) Versus a Combination With a Higher Proportion of DCI (3.6:1) in the Oocyte Quality and Pregnancy Rates in Women With PCOS
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the present study is to evaluate the effect of increasing the proportion of D-chiro-inositol (DCI) in a combination with myo-inositol (MYO) in improving fertility in women with polycystic ovarian syndrome (PCOS). Sixty women diagnosed with PCOS will randomly take twice a day for 12 weeks a capsule containing 550 mg of myo-inositol and 150 mg of D-chiro-inositol or capsules containing 550 mg of myo-inositol and 13.8 mg of D-chiro-inositol.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Infertility | — | UNRESOLVED | — |
| Polycystic Ovarian Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| D-chiro-inositol | Drug | — | UNRESOLVED |
| Myoinositol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 550 mg of MYO and 150 mg of DCI
- description
- Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 150 mg of D-chiro-inositol.
- interventionNames
- Drug: D-chiro-inositol
- Drug: Myoinositol
- type
- ACTIVE_COMPARATOR
- label
- 550 mg of MYO and 13.8 mg of DCI
- description
- Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 13.8 mg of D-chiro-inositol.
- interventionNames
- Drug: D-chiro-inositol
- Drug: Myoinositol
Primary outcomes (1)
- measure
- Pregnancy rate
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Being diagnosed with PCOS according to Rotterdam criteria. * Being in in vitro fertilization treatment. * Body mass index less than 30 kg/m2. * Accept freely to participate in the study and sign the informed consent document. Exclusion Criteria: * Contraindication to perform techniques of assisted reproduction or stimulation of ovulation. * Advanced state of endometriosis (III or IV). * Classified as poor responder in fertility treatment. * Premature ovarian failure. * Severe male factor (cryptozoospermia). * Few expectations of compliance and/or collaboration.
References
Publications (0)
Data not yet available